Author

M. Jugold

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:spatial domain detection· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

A. Ernst· 2 shared F. Devens· 2 shared M. Sill· 2 shared M. Simovic· 2 shared S. Pfister· 2 shared A. Abdollahi· 1 shared A. Korshunov· 1 shared A. Li· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Ernst

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial and temporal transcriptomics of SHH-medulloblastoma with chromothripsis identifies multiple genetic clones that resist to treatment and lead to relapse

I. Kats, H. S. Schreiber, M. Simovic, P. Sant, J.-P. Mallm, A. Li, P. Velmurugan, S. Weil, F. Devens, M. Sill, M. Jugold, M. Moustafa, A. Abdollahi, F. Winkler, A. Korshunov, , A. Ernst

This study uses spatial transcriptomics to analyze chromothriptic medulloblastomas, revealing higher intra-tumour heterogeneity, treatment resistance, and relapse mechanisms through clone-specific features.

bioRxiv · Mar 3, 2023 · PreprintCancer Biology

A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis

U. Khalid, M. Simovic, M. Iskar, J. K. L. Wong, R. Kumar, M. Jugold, M. Sill, M. Bolkestein, T. Kolb, M. Hergt, F. Devens, J. Ecker, M. Kool, T. Milde, F. Westermann, , A. Ernst

The paper identifies a synergistic effect between HDAC and PARP inhibitors in childhood tumors with chromothripsis, validated through drug screening and in vivo models.

bioRxiv · Apr 22, 2021Cancer Biology